Our Services
Medical Information
Helpful Resources
Published on: 7/10/2026
Discontinuing Dupixent removes IL-4 and IL-13 signal blockade, allowing eosinophils and mucosal inflammation to resurge. This often triggers nasal polyp regrowth within weeks to months. Underlying drivers—allergies, structural sinus abnormalities, and eosinophilic memory—remain unchanged by the medication and fuel this rebound effect.
Several factors influence how quickly and severely polyps return, and specific strategies can help slow recurrence. Because symptoms like nasal congestion, facial pressure, reduced smell, and post-nasal drip can overlap with allergies, infections, or other sinus conditions, identifying what's actually driving your symptoms is critical for choosing the right next step. A free, instant, online symptom check can help you clarify your situation in minutes, understand possible causes, and decide whether to contact your specialist, adjust your care plan, or explore alternative treatments—before symptoms escalate.
Reviewed for medical accuracy: 07/09/2026
Stopping Dupixent do nasal polyps grow back fast? Many people wonder what happens when they pause or stop dupilumab (Dupixent) treatment for chronic sinusitis with nasal polyps. Dupixent can dramatically shrink polyps and relieve symptoms, but nasal polyps often return once the drug is discontinued. Here's the real science behind why and how quickly that can happen, without sugar-coating the facts or causing undue alarm.
Nasal polyps are benign, grape-like growths inside the nasal passages and sinuses. They develop due to chronic inflammation and are most common in people with:
Key drivers of polyp growth include:
Left unchecked, this cycle of inflammation leads to polyp formation, nasal congestion, loss of smell, headaches, and recurrent infections.
Dupixent is a biologic therapy that targets the root of type 2 inflammation: it blocks the receptors for two key cytokines, IL-4 and IL-13. By interrupting these signals, Dupixent:
Clinical trials (SINUS-24 and SINUS-52) showed that most patients experienced significant polyp size reduction and better symptom scores within 16 weeks of starting Dupixent, with continued benefit through one year.
When you stop Dupixent, the underlying drivers of inflammation can re-emerge:
Cytokine Rebound
Persistent Inflammatory Triggers
Mucosal Remodeling
Eosinophil Memory
Because these processes aren't permanently reversed by Dupixent, polyps can regrow once the blockade on IL-4/IL-13 is lifted.
The speed of regrowth varies by individual but in many trials and real-world reports:
Factors that influence regrowth speed include:
In essence, stopping Dupixent often allows the same inflammatory environment to re-establish itself, which can lead to relatively fast polyp return.
This doesn't mean everyone will have the exact same timeline, but it underscores that nasal polyps are a chronic condition driven by ongoing inflammation.
If you or your doctor decide to pause Dupixent, consider these strategies to slow polyp regrowth:
• Intranasal corticosteroids
• Short courses of oral steroids (for flare-ups)
• Saline rinses and nasal hygiene
• Allergen avoidance and allergy immunotherapy (when relevant)
• Aspirin desensitization (in AERD patients)
• Surgical options (endoscopic sinus surgery to widen sinus openings)
• Lifestyle adjustments (e.g., smoking cessation, air filtration)
Regular follow-up with an ENT specialist or allergist can help you monitor for early signs of regrowth and adjust your plan accordingly.
Dupixent is highly effective but also expensive, and some patients face insurance or access challenges. Discuss with your care team:
Shared decision-making ensures you get relief while managing side effects, budget, and quality of life.
If you notice any of the following after stopping Dupixent, talk to your doctor promptly:
If you're experiencing new or worsening symptoms and want help understanding what they might mean, you can use Ubie's free AI symptom checker to get personalized insights about your condition in just 3 minutes—it's a quick way to determine whether you should seek immediate care or schedule a routine appointment.
Always speak to your healthcare provider about anything that could be life-threatening or serious.
Nasal polyps are a chronic, inflammatory condition. Stopping Dupixent may lead to fairly rapid regrowth, but proactive measures and close medical supervision can help you maintain control over your symptoms. Always speak to a doctor about any serious or life-threatening concerns.
(References)
* Luong A, Peters AT, Laidlaw T, Han JK, Kern RC, Schlosser RJ, Sacks WJ, Lam K, Mullol J, Hellings PW, Sanyal S, Fan C, Pirozzi G, Yancopoulos GD, Staudinger H, Mannent LP, Weinreich DM, Gandhi NA, Khan A, Geng B. Sustained improvement and disease recurrence after dupilumab discontinuation in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2023 Dec;11(12):3736-3747.e3. doi: 10.1016/j.jaip.2023.08.016. Epub 2023 Aug 21. PMID: 37604313.
* Hopkins C, Soni M, Marfaing-Koka A, Staudinger H, Mannent LP, Geng B, Fan C, Yancopoulos GD, Weinreich DM, Gandhi NA, Khan A, Sacks WJ. Disease control and relapse after dupilumab treatment in chronic rhinosinusitis with nasal polyps: a real-world study. Laryngoscope. 2024 Jan;134(1):251-258. doi: 10.1002/lary.30906. Epub 2023 Jul 4. PMID: 37398939.
* Chen C, Zhang H, Zhang H, Yuan Z. Recurrence of chronic rhinosinusitis with nasal polyps after cessation of dupilumab: A systematic review and meta-analysis. Front Pharmacol. 2023 Sep 8;14:1248039. doi: 10.3389/fphar.2023.1248039. PMID: 37744315; PMCID: PMC10515152.
* Zhang M, Chang C, Chitsuthipakorn W, Chen YC, Chu CW, Chien TJ, Lin HC, Weng Z, Hung CH, Chien CY. Real-World Effectiveness of Dupilumab for Chronic Rhinosinusitis With Nasal Polyps: A Multi-Institutional Study on Discontinuation and Relapse. Am J Rhinol Allergy. 2024 Jan;38(1):110-117. doi: 10.1177/19458924231210870. Epub 2023 Nov 14. PMID: 37965385.
* Arakawa S, Masuda S, Hirai T, Yamamoto H, Haruna S, Asano K, Oishi H. Risk factors for relapse after discontinuation of dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps. Eur Arch Otorhinolaryngol. 2024 Feb;281(2):653-659. doi: 10.1007/s00405-024-08428-w. Epub 2024 Feb 5. PMID: 38317075.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.